Aptose Biosciences amends employment agreements with CEO, CMO, and CFO to harmonize change of control provisions

Aptose Biosciences Inc.

CEO William Rice's base salary increased to $648,960, with bonus up to 55% of base and auto allowance of $18,000.
CMO Rafael Bejar's salary increased to $509,600, added Senior VP title, and updated severance for change of control.
CFO Fletcher Payne's salary increased to $479,440, added Chief Business Officer and Corporate Secretary titles.
Each amendment harmonizes change of control provisions and updates compensation terms for the three executives.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Rafael Bejar

Senior Vice President and Chief Medical Officer

APTOF · Aptose Biosciences Inc.

Effective: 2024-04-29
Filed: May 1, 2024, 7:59 PM ET

The amendment also added the title of Senior Vice President to Mr. Bejar’s position,

Role change

Fletcher Payne

Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary

APTOF · Aptose Biosciences Inc.

Effective: 2024-04-29
Filed: May 1, 2024, 7:59 PM ET

The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rafael Bejar was appointed as Senior Vice President and Chief Medical Officer at Aptose Biosciences Inc..

Action: appointed
Role: Senior Vice President and Chief Medical Officer

Exact text from the filing

The amendment also added the title of Senior Vice President to Mr. Bejar’s position,

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Fletcher Payne was appointed as Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary at Aptose Biosciences Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary

Exact text from the filing

The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.

View on SEC.gov

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.